AfatinibVarious toxicities and drug resistance following off-label treatment: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1880卷 / 1期

关键词：

D O I：

10.1007/s40278-021-04856-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：22 / 22

相关论文

共 50 条

[31] RivoceranibHaemafecia following off-label treatment: case report
[J]. Reactions Weekly, 2018, 1721 (1) : 263 - 263
[32] Multiple drugsVarious toxicities following off-label use and misuse, and drug ineffective: case report
[J]. Reactions Weekly, 2022, 1887 (1) : 509 - 509
[33] Multiple drug overdoseVarious toxicities and off-label use: case report
[J]. Reactions Weekly, 2021, 1853 (1) : 311 - 311
[34] VenetoclaxNeutropenia following off-label treatment: case report
[J]. Reactions Weekly, 2021, 1849 (1) : 412 - 412
[35] DenosumabVarious toxicities following off-label treatment: 2 case reports
[J]. Reactions Weekly, 2019, 1781 (1) : 136 - 136
[36] BuprenorphineVarious toxicities following off-label treatment: 2 case reports
[J]. Reactions Weekly, 2020, 1832 (1) : 81 - 81
[37] LarotrectinibAcquired drug resistance and liver toxicity following off-label use: case report
[J]. Reactions Weekly, 2023, 1978 (1) : 221 - 221
[38] NivolumabDrug resistance following off-label therapy: case report
[J]. Reactions Weekly, 2020, 1808 (1) : 228 - 228
[39] Mutiple drugsVarious toxicities, drug ineffective and off-label use: case report
[J]. Reactions Weekly, 2023, 1974 (1) : 272 - 272
[40] AntineoplasticsVarious toxicities, treatment failure and off-label use: case report
[J]. Reactions Weekly, 2023, 1972 (1) : 50 - 50

← 1 2 3 4 5 →